Development of a capture ELISA to determine kinetics of soluble CD25 following in vitro and in vivo stimulation of duck peripheral blood monocytes

Veterinary Immunology and Immunopathology

Volumn 140, Issue 1-2, 2011, Pages 102-109

  Huang, Zhenyu ^a,b   Fang, Jie ^a   Gu, Jianyou ^a,b   Yan, Yan ^a,b   Zhou, Jiyong ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Antigen capture ELISA; Avian influenza virus; CD25 + cells; Duck; Riemerella anatipestifer; Soluble CD25

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA; CONCANAVALIN A;

ANIMAL CELL; ANTIGEN CAPTURE ENZYME LINKED IMMUNOSORBENT ASSAY; ARTICLE; AVIAN INFLUENZA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DUCK; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H9N2; LIMIT OF DETECTION; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RIEMERELLA ANATIPESTIFER; UPREGULATION; ANIMAL; ANIMAL DISEASE; BIOSYNTHESIS; BLOOD; FLAVOBACTERIACEAE; FLAVOBACTERIACEAE INFECTION; FLOW CYTOMETRY; IMMUNOLOGY; INFLUENZA VIRUS A H5N1; KINETICS; LYMPHOCYTE COUNT; METABOLISM; METHODOLOGY; MICROBIOLOGY; MONONUCLEAR CELL; T LYMPHOCYTE; VIROLOGY;

ANAS; AVES; AVIAN INFLUENZA VIRUS; MAMMALIA; RIEMERELLA ANATIPESTIFER;

ANIMALS; CONCANAVALIN A; DUCKS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLAVOBACTERIACEAE; FLAVOBACTERIACEAE INFECTIONS; FLOW CYTOMETRY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA IN BIRDS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KINETICS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE COUNT; T-LYMPHOCYTES;

EID: 79960982133     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2010.11.021     Document Type: Article

References (51)

1. Akin C., Schwartz L.B., Kitoh T., Obayashi H., Worobec A.S., Scott L.M., Metcalfe D.D. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood 2000, 96:1267-1273.
2. Banerjee S.B.a.C.D. Development of a highly sensitive direct microtiter plate ELISA for human serum testosterone. Indian J. Clin. Biochem. 1999, 14:19-25.
3. Belkaid Y., Rouse B.T. Natural regulatory T cells in infectious disease. Nat. Immunol. 2005, 6:353-360.
4. Bien E., Rapala M., Krawczyk M., Balcerska A. The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas. J. Cancer Res. Clin. Oncol. 2010, 136:293-305.
5. Boyano M.D., Garcia-Vazquez M.D., Lopez-Michelena T., Gardeazabal J., Bilbao J., Canavate M.L., Galdeano A.G., Izu R., Diaz-Ramon L., Raton J.A., Diaz-Perez J.L. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br. J. Cancer 2000, 83:847-852.
6. Brusko T.M., Wasserfall C.H., Hulme M.A., Cabrera R., Schatz D., Atkinson M.A. Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation. PLoS One 2009, 4:e7980.
7. Cabrera R., Ararat M., Cao M., Xu Y., Wasserfall C., Atkinson M.A., Liu C., Nelson D.R. Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). Dig. Dis. Sci. 2010, 55:484-495.
8. Crowther, J.R., 2000. The ELISA guidebook. Methods Mol. Biol. 149 (III-IV), 1-413.
9. Diamantstein T., Osawa H., Mouzaki A., Josimovic-Alasevic O. Regulation of interleukin-2 receptor expression and receptor release. Mol. Immunol. 1986, 23:1165-1172.
10. El-Shafey E.M., El-Nagar G.F., El-Bendary A.S., Sabry A.A., Selim A.G. Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus. Iran J. Kidney Dis. 2008, 2:80-85.
11. Giannitrapani L., Cervello M., Soresi M., Notarbartolo M., La Rosa M., Virruso L., D'Alessandro N., Montalto G. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann. N.Y. Acad. Sci. 2002, 963:46-52.
12. Gu J., Teng Q., Huang Z., Ruan X., Zhou J. Identification of the functional interleukin-2 binding domain of the chicken common cytokine receptor gamma chain. Dev. Comp. Immunol. 2010, 34:258-263.
13. Hsiao S.H., Lee M.S., Lin H.Y., Su Y.C., Ho H.C., Hwang J.H., Lee C.C., Hung S.K. Clinical significance of measuring levels of tumor necrosis factor-alpha and soluble interleukin-2 receptor in nasopharyngeal carcinoma. Acta Otolaryngol. 2009, 1-5.
14. Kami M., Matsumura T., Tanaka Y., Mikami Y., Miyakoshi S., Ueyama J., Morinaga S., Mori S., Machida U., Kanda Y., Chiba S., Sakamaki H., Hirai H., Muto Y. Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: a true marker of acute graft-versus-host disease. Leuk. Lymphoma 2000, 38:533-540.
15. Karlsson H., Nassberger L. Influence of compounds affecting synthesis, modification and transport of proteins on the expression and release of interleukin-2 receptor. Immunol. Cell Biol. 1995, 73:81-88.
16. Kinter A.L., Hennessey M., Bell A., Kern S., Lin Y., Daucher M., Planta M., McGlaughlin M., Jackson R., Ziegler S.F., Fauci A.S. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J. Exp. Med. 2004, 200:331-343.
17. Kohm A.P., McMahon J.S., Podojil J.R., Begolka W.S., DeGutes M., Kasprowicz D.J., Ziegler S.F., Miller S.D. Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+T regulatory cells. J. Immunol. 2006, 176:3301-3305.
18. Loughnan M.S., Sanderson C.J., Nossal G.J. Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:3115-3119.
19. Makis A.C., Galanakis E., Hatzimichael E.C., Papadopoulou Z.L., Siamopoulou A., Bourantas K.L. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis. J. Infect. 2005, 51:206-210.
20. Minami Y., Kono T., Miyazaki T., Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu. Rev. Immunol. 1993, 11:245-268.
21. Mond J.J., Thompson C., Finkelman F.D., Farrar J., Schaefer M., Robb R.J. Affinity-purified interleukin 2 induces proliferation of large but not small B cells. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:1518-1521.
22. Monsalve-De Castillo F., Romero T.A., Estevez J., Costa L.L., Atencio R., Porto L., Callejas D. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clin. Diagn. Lab. Immunol. 2002, 9:1372-1375.
23. Moore A.C., Gallimore A., Draper S.J., Watkins K.R., Gilbert S.C., Hill A.V. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. J. Immunol. 2005, 175:7264-7273.
24. Novikov V.V., Egorova N.I., Kurnikov G.Y., Evsegneeva I.V., Baryshnikov A.Y., Karaulov A.V. Serum levels of soluble HLA and IL-2R molecules in patients with urogenital chlamydia infection. Adv. Exp. Med. Biol. 2007, 601:285-289.
25. Nuallain E.M., Davis W.C., Fisher A.D., Monaghan M.L. Development of a sandwich immunoassay for the detection of soluble bovine interleukin-2 receptor-alpha (sIL-2R-alpha) and its use to measure cell-mediated immunity in cattle. Vet. Res. Commun. 1997, 21:19-28.
26. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999, 59:3128-3133.
27. Pockley A.G., Williams S., Reid S.D., Bowles M.J. Development of an enzyme immunoassay for rat soluble interleukin-2 receptors. J. Immunol. Methods 1995, 182:81-84.
28. Rose-John S., Heinrich P.C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 1994, 300(Pt 2):281-290.
29. Rubin L.A., Galli F., Greene W.C., Nelson D.L., Jay G. The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine 1990, 2:330-336.
30. Rubin L.A., Kurman C.C., Biddison W.E., Goldman N.D., Nelson D.L. A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma 1985, 4:91-102.
31. Rubin L.A., Kurman C.C., Fritz M.E., Biddison W.E., Boutin B., Yarchoan R., Nelson D.L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 1985, 135:3172-3177.
32. Rubinstein M.P., Kovar M., Purton J.F., Cho J.H., Boyman O., Surh C.D., Sprent J. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:9166-9171.
33. Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., Kuniyasu Y., Nomura T., Toda M., Takahashi T. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 2001, 182:18-32.
34. Shang S.B., Li Y.F., Guo J.Q., Wang Z.T., Chen Q.X., Shen H.G., Zhou J.Y. Development and validation of a recombinant capsid protein-based ELISA for detection of antibody to porcine circovirus type 2. Res. Vet. Sci. 2008, 84:150-157.
35. Smith K.A. The interleukin 2 receptor. Annu. Rev. Cell. Biol. 1989, 5:397-425.
36. Sugimoto K., Ikeda F., Stadanlick J., Nunes F.A., Alter H.J., Chang K.M. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003, 38:1437-1448.
37. Taguchi O., Takahashi T. Administration of anti-interleukin-2 receptor alpha antibody in vivo induces localized autoimmune disease. Eur. J. Immunol. 1996, 26:1608-1612.
38. Takahashi T., Kuniyasu Y., Toda M., Sakaguchi N., Itoh M., Iwata M., Shimizu J., Sakaguchi S. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 1998, 10:1969-1980.
39. Teng Q.Y., Zhou J.Y., Wu J.J., Guo J.Q., Shen H.G. Characterization of chicken interleukin 2 receptor alpha chain, a homolog to mammalian CD25. FEBS Lett. 2006, 580:4274-4281.
40. Thornton A.M., Shevach E.M. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 2000, 164:183-190.
41. Tsudo M., Uchiyama T., Uchino H. Expression of Tac antigen on activated normal human B cells. J. Exp. Med. 1984, 160:612-617.
42. Uchiyama T., Hori T., Tsudo M., Wano Y., Umadome H., Tamori S., Yodoi J., Maeda M., Sawami H., Uchino H. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J. Clin. Invest. 1985, 76:446-453.
43. Vahlenkamp T.W., Tompkins M.B., Tompkins W.A. Feline immunodeficiency virus infection phenotypically and functionally activates immunosuppressive CD4+CD25+ T regulatory cells. J. Immunol. 2004, 172:4752-4761.
44. Verhagen A.M., Kimpton W.G., Nash A.D. Development of a sandwich immunoassay for the detection of soluble ovine IL-2R alpha chain. Vet. Immunol. Immunopathol. 1994, 42:287-300.
45. Waldmann T.A., Greene W.C., Sarin P.S., Saxinger C., Blayney D.W., Blattner W.A., Goldman C.K., Bongiovanni K., Sharrow S., Depper J.M., et al. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sezary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. J. Clin. Invest. 1984, 73:1711-1718.
46. Wang J., Fang J., Guo J., Teng Q., Huang Z., Gu J., Shen H., Zhou J. Molecular cloning and characterization of Duck CD25. Vet. Immunol. Immunopathol. 2007, 117:266-274.
47. Zhang Z., Zhang M., Garmestani K., Talanov V.S., Plascjak P.S., Beck B., Goldman C., Brechbiel M.W., Waldmann T.A. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood 2006, 108:1007-1012.
48. Zhou J., Sun W., Wang J., Guo J., Yin W., Wu N., Li L., Yan Y., Liao M., Huang Y., Luo K., Jiang X., Chen H. Characterization of the H5N1 highly pathogenic avian influenza virus derived from wild pikas in China. J. Virol. 2009, 83:8957-8964.
49. Zhou J.Y., Chen J.G., Wang J.Y., Wu J.X., Gong H. cDNA cloning and functional analysis of goose interleukin-2. Cytokine 2005, 30:328-338.
50. Zhou J.Y., Shen H.G., Chen H.X., Tong G.Z., Liao M., Yang H.C., Liu J.X. Characterization of a highly pathogenic H5N1 influenza virus derived from bar-headed geese in China. J. Gen. Virol. 2006, 87:1823-1833.
51. Zhou J.Y., Wang J.Y., Chen J.G., Wu J.X., Gong H., Teng Q.Y., Guo J.Q., Shen H.G. Cloning, in vitro expression and bioactivity of duck interleukin-2. Mol. Immunol. 2005, 42:589-598.